| Literature DB >> 31455308 |
Corinne Legeret1,2, Laura Mählmann3, Markus Gerber4, Nadeem Kalak3, Henrik Köhler5, Edith Holsboer-Trachsler3, Serge Brand3,4,6, Raoul Furlano7.
Abstract
BACKGROUND: Evidence is growing that both short- and long-term physical exercise have the potential to positively impact on the physiological system related to inflammatory indices, though, such patterns are unknown for pediatric patients with Inflammatory Bowel Disease (IBD). The aim of the present intervention study was to investigate the influence of a single bout and chronic moderate-intensity exercise on IBD-related inflammatory indices and exercise capacity among pediatric individuals with IBD and healthy controls.Entities:
Keywords: Exergaming; Inflammation; Inflammatory bowel disease; Pediatrics; Physical activity
Year: 2019 PMID: 31455308 PMCID: PMC6710863 DOI: 10.1186/s12887-019-1680-7
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Characteristics and medication of IBD patients
| Patient | Age in years | Diagnosis | Medication | PUCAI/PCDAI before 8-week intervention | PUCAI/PCDAI after 8-week intervention |
|---|---|---|---|---|---|
| 1 | 14.16 | Crohn’s disease | Infliximab 5 mg/kg 6-weekly and Azathioprine 100 mg/ day | 25 | 15 |
| 2 | 17.08 | Crohn’s disease | Infliximab 5 mg/kg 6-weekly | 30 | 25 |
| 3 | 11.75 | Ulcerative colitis | Azathioprine 100 mg/day | 0 | 0 |
| 4 | 17.16 | Crohn’s disease | Ustekinumab 45 mg s.c. 8-weekly | 5 | 5 |
| 5 | 13.41 | Ulcerative colitis | Golimumab 50 mg s.c. every 4-weekly | 0 | 5 |
| 6 | 14.16 | Crohn’s disease | Mesalazine 2 g/day | 0 | 5 |
| 7 | 13.83 | Crohn’s disease | Azathioprine 75 mg daily | 0 | 0 |
| 8 | 12.58 | Ulcerative colitis | Golimumab 50 mg 4-weekly | 25 | 20 |
| 9 | 13.66 | Crohn’s disease | Infliximab 5 mg/kg 8-weekly Azathioprine 100 mg/day | 5 | 0 |
| 10 | 12.33 | Crohn’s disease | Infliximab 5 mg/kg 8-weekly | 5 | 0 |
| 11 | 16.33 | Crohn’s disease | Azathioprine 75 mg/day | 0 | 0 |
| 12 | 17.75 | Ulcerative colitis | Azathioprine 100 mg/day | 25 | 20 |
| 13 | 4.58 | Ulcerative colitis | Mesalazine 500 mg/day | 0 | 0 |
| 14 | 23.16 | Ulcerative colitis | no treatment at this time | 0 | 0 |
| 15 | 17.33 | Crohn’s disease | Infliximab 5 mg/kg 7-weekly | 20 | 15 |
| 16 | 7.58 | Ulcerative colitis | Mesalazine 1 g/day Prednisone 20 mg/10 mg/day | 40 | 30 |
| 17 | 15.33 | Crohn’s disease | Infliximab 5 mg/kg 8weekly | 5 | 0 |
| 18 | 14.16 | Indeterminate colitis | Infliximab 10 mg/kg 6-weekly | 0 | 5 |
| 19 | 3.0 | Ulcerative colitis | Mesalazine 500 mg/day Prednisone 15 mg/day | 15 | 10 |
| 20 | 10.66 | Ulcerative colitis | Mesalazine 1 g/ day | 0 | 0 |
| 21 | 10.5 | Crohn’s disease | no treatment at this point | 5 | 5 |
Sample Characteristics
| IBD-AD | IBD-RE | HC | |
|---|---|---|---|
|
|
|
| |
| Age in years | 12.78 ± 3.25 | 13.64 ± 2.96 | 12.38 ± 3.23 |
| Female | 2 (28.6%) | 8 (57.14%) | 15 (62.5%) |
| IBD | |||
| Ulcerative colitis | 4 | 5 | |
| Crohn’s Disease | 3 | 8 | |
| Indeterminate colitis | 1 | ||
| Time since diagnosis | 111.54 ± 83.35 | 124.74 ± 88.19 | |
| Height (cm) | 153.48 ± 17.53 | 152.69 ± 12.02 | 152.26 ± 18.0 |
| Weight (kg) | 45.28 ± 15.85 | 42.79 ± 12.83 | 44.37 ± 15.75 |
| Weight to height (%) | 44.08 ± 3.07 | 42.94 ± 2.13 | 42.77 ± 3.49 |
| BMI | 18.6 ± 3.37 | 17.91 ± 2.78 | 18.36 ± 3.16 |
Notes: N = 44, IBD-AD = IBD in an active state of the disease, IBD-RE = IBD in remission, HC = Healthy Control; all data presented in mean ± standard deviation
Results
| IBD-AD | IBD-RE | HC |
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
| |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Inflammation before and after a single bout of exercise | |||||||||||||||
| ESR | 11.83 ± 8.06 | 9.67 ± 7.4 | 11.83 ± 13.17 | 8.5 ± 10.11 | 6.05 ± 6.57 | 7.59 ± 9.42 | 0.61 | .44 | 0.02 | 0.97 | .39 | 0.05 | 1.19 | .32 | 0.06 |
| Albumin | 19.36 ± 17.79 | 20.04 ± 18.57 | 20.37 ± 18.77 | 21.08 ± 19.5 | 21.49 ± 18.63 | 22.36 ± 19.44 | 17.80 | .00 | 0.30 | 0.05 | .96 | 0.00 | 0.13 | .88 | 0.01 |
| CRP | 4.44 ± 5.57 | 4.52 ± 5.7 | 3.02 ± 4.56 | 3.02 ± 4.51 | 0.67 ± 0.84 | 0.7 ± 0.84 | 1.91 | .18 | 0.05 | 4.10 | .02 | 0.18 | 0.85 | .43 | 0.04 |
| Cortisol | 289.75 ± 159.82 | 285.63 ± 191.25 | 248.31 ± 138.53 | 242 ± 146.79 | 203.83 ± 109.8 | 208.35 ± 104.4 | 0.06 | .81 | 0.00 | 1.26 | .29 | 0.06 | 0.23 | .80 | 0.01 |
| Hemoglobin | 126 ± 19.57 | 129.88 ± 21.03 | 135.31 ± 15.63 | 135.77 ± 15.88 | 135.91 ± 12.05 | 136.78 ± 13.57 | 8.05 | .01 | 0.16 | 0.96 | .39 | 0.04 | 2.42 | .10 | 0.11 |
| Erytrozytes | 4.78 ± 0.28 | 4.93 ± 0.25 | 4.87 ± 0.51 | 4.90 ± 0.52 | 4.87 ± 0.35 | 4.89 ± 0.37 | 11.86 | .00 | 0.22 | 0.01 | .99 | 0.00 | 3.23 | .05 | 0.14 |
| Hematocrit | 37.06 ± 4.13 | 38.29 ± 4.2 | 38.17 ± 3.83 | 38.62 ± 3.98 | 38.7 ± 3.11 | 39.02 ± 3.41 | 17.71 | .00 | 0.30 | 0.33 | .72 | 0.02 | 2.71 | .08 | 0.12 |
| Thrombocytes | 416.5 ± 181.38 | 402.13 ± 102.78 | 310.46 ± 60.80 | 334.85 ± 68.85 | 270.87 ± 45.59 | 293.52 ± 55.62 | 1.88 | .18 | 0.04 | 8.38 | .00 | 0.29 | 2.01 | .15 | 0.09 |
| Leukocytes | 9.5 ± 1.93 | 11.05 ± 2.2 | 9.28 ± 2.71 | 10.75 ± 3.11 | 8.23 ± 1.26 | 9.46 ± 1.95 | 38.54 | .00 | 0.48 | 2.14 | .13 | 0.09 | 0.21 | .81 | 0.01 |
| Inflammation before and after 8-week ET intervention | |||||||||||||||
| ESR | 24.5 ± 26.33 | 11.5 ± 16.56 | 11.83 ± 13.17 | 6.33 ± 5.85 | 6.24 ± 6.66 | 7.19 ± 7.77 | 8.69 | .01 | 0.19 | 3.02 | .06 | 0.14 | 4.21 | .02 | 0.19 |
| Albumin | 24.83 ± 17.31 | 28.42 ± 19.24 | 20.37 ± 18.77 | 23.28 ± 18.73 | 23.14 ± 18.69 | 28.58 ± 17.99 | 2.47 | .12 | 0.06 | 0.27 | .76 | 0.01 | 0.14 | .87 | 0.01 |
| CRP | 4.44 ± 5.57 | 0.9 ± 0.85 | 3.02 ± 4.56 | 0.63 ± 0.86 | 0.72 ± 0.87 | 0.92 ± 1.56 | 10.40 | .00 | 0.23 | 2.31 | .11 | 0.12 | 4.47 | .02 | 0.20 |
| Cortisol | 214.67 ± 85.67 | 161.83 ± 79.75 | 248.31 ± 138.53 | 227.54 ± 111.15 | 209.05 ± 109.93 | 222.33 ± 99.53 | 0.92 | .34 | 0.02 | 0.61 | .55 | 0.03 | 0.88 | .42 | 0.05 |
| Hemoglobin | 133.33 ± 11.55 | 136.5 ± 9.71 | 135.31 ± 15.63 | 135.54 ± 13.85 | 135.5 ± 12.16 | 133.68 ± 12.04 | 0.23 | .64 | 0.01 | 0.02 | .98 | 0.00 | 1.66 | .20 | 0.08 |
| Erytrozyten | 4.78 ± 0.33 | 4.86 ± 0.42 | 4.87 ± 0.51 | 4.87 ± 0.44 | 4.85 ± 0.35 | 4.77 ± 0.25 | 0.03 | .85 | 0.00 | 0.05 | .95 | 0.00 | 0.80 | .46 | 0.04 |
IBD-AD IBD in an active state of the disease, IBD-RE IBD in remission, HC Healthy Control, BSG Blood Sedimentation Grade, CRP C-Reactive Protein
Notes. N = 44; degrees of freedom always = 2, 41; p < .05 statistically significant; all data presented in mean (M) ± standard deviation; effect sizes: small (s) = .01 ≤ ηp2 ≤ .059, medium (m) = .06 ≤ ηp2 ≤ .139, or large (l) = ηp2 ≥ .14